Literature DB >> 23768465

Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer.

Marzia Lotrionte1, Elena Cavarretta, Antonio Abbate, Eleonora Mezzaroma, Eugenia De Marco, Silvia Di Persio, Francesco Loperfido, Giuseppe Biondi-Zoccai, Giacomo Frati, Giovanni Palazzoni.   

Abstract

Anthracyclines are established cardiotoxic agents; however, the exact extent and time course of such cardiotoxicity has not been appraised in detail. We aimed to exploit serial measurements of standard and tissue Doppler imaging (TDI) echocardiographic parameters collected in a prospective clinical trial to clarify the outlook of cardiac function during and long after anthracycline chemotherapy. Women enrolled in a randomized trial focusing on liposomal doxorubicin-based chemotherapy for breast cancer and providing ≥4 separate echocardiographic assessments were included. Repeat-measure nonparametric analyses were used to appraise changes over time in the standard and tissue Doppler imaging echocardiographic parameters. A total of 39 patients with serial imaging evaluations were enrolled. Significant temporal changes were found for the left ventricular ejection fraction and diastolic parameters, despite different temporal trends. Specifically, the left ventricular ejection fraction exhibited a V-shaped trend, decreasing initially from 63% to 61% but then recovering to 64% (p <0.001), with a similar trend in the TDI E/Em ratio (p = 0.011). In contrast, persistent impairments typical of an L-shaped trend were found for the E wave (p = 0.006), TDI lateral Em wave (p = 0.001), and TDI septal Em wave (p = 0.001). In conclusion, subclinical temporal changes in the standard and TDI echocardiographic parameters after anthracycline chemotherapy showed a distinctive pattern of transient impairment followed by full recovery of the left ventricular ejection fraction versus a persistent impairment of the diastolic parameters, which must be taken into account in the everyday treatment of such patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23768465     DOI: 10.1016/j.amjcard.2013.05.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.

Authors:  Patrick L Stevens; Daniel J Lenihan
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

Review 2.  Role of echocardiography in the management of cardiac disease in women.

Authors:  Wan Joo Shim
Journal:  J Cardiovasc Ultrasound       Date:  2014-12-26

3.  Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells.

Authors:  Isotta Chimenti; Francesca Pagano; Elena Cavarretta; Francesco Angelini; Mariangela Peruzzi; Antonio Barretta; Ernesto Greco; Elena De Falco; Antonino G M Marullo; Sebastiano Sciarretta; Giuseppe Biondi-Zoccai; Giacomo Frati
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

Review 4.  MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?

Authors:  Elena Cavarretta; Giacomo Frati
Journal:  Biomed Res Int       Date:  2016-11-02       Impact factor: 3.411

5.  Cardiotoxicity due to chemotherapy for breast cancer: the dark side of the moon.

Authors:  Mariangela Peruzzi; Giovanni Palazzoni; Giuseppe Biondi-Zoccai; Marzia Lotrionte
Journal:  Anatol J Cardiol       Date:  2014-12-25       Impact factor: 1.596

6.  Real-time three-dimensional echocardiography predicts cardiotoxicity induced by postoperative chemotherapy in breast cancer patients.

Authors:  Fang Zhou; Lin Niu; Min Zhao; Wei-Xing Ni; Jian Liu
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

Review 7.  Multimodality Imaging in Cardiooncology.

Authors:  Fausto Pizzino; Giampiero Vizzari; Rubina Qamar; Charles Bomzer; Scipione Carerj; Concetta Zito; Bijoy K Khandheria
Journal:  J Oncol       Date:  2015-08-02       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.